1-2 of 2
María Díez-Campelo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

AML typical mutations (CEBPA, FLT3, and NPM1) identify a high-risk CMML independent of CPSS-Mol classification

Sandra Castaño-Díez, Mònica López-Guerra, Inés Zugasti, Xavier Calvo, Felicitas Isabel Schulz, Alejandro Avendaño, Elvira Mora, Jose Francisco Falantes-González, Gemma Azaceta, Mariam Ibañez, Tzu-Hua Chen-Liang, Cristina Notario Mc Donnell, Neus Amer-Salas, Laura Palomo, Helena Pomares, Jordi Vila, Teresa Bernal del Castillo, Carlos Jiménez-Vicente, Daniel Esteban, Francesca Guijarro, José Ramón Álamo Moreno, Albert Cortés-Bullich, Víctor Torrecillas-Mayayo, Ana Triguero, Lucía Mont-de Torres, Ester Carcelero, Aina Cardús, Ulrich Germing, Beate Betz, Maria Rozman, Leonor Arenillas, Lurdes Zamora, María Díez-Campelo, Blanca Xicoy, Jordi Esteve, Marina Díaz-Beyá
Journal: Blood Advances
Blood Adv bloodadvances.2024013648.
https://doi.org/10.1182/bloodadvances.2024013648
Published: 2024
Includes: Supplemental data
Journal Articles

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

Clinical Trials & Observations
Lionel Adès, Larisa Girshova, Vadim A. Doronin, María Díez-Campelo, David Valcárcel, Suman Kambhampati, Nora-Athina Viniou, Dariusz Woszczyk, Raquel De Paz Arias, Argiris Symeonidis, Achilles Anagnostopoulos, Eduardo Ciliao Munhoz, Uwe Platzbecker, Valeria Santini, Robert J. Fram, Ying Yuan, Sharon Friedlander, Douglas V. Faller, Mikkael A. Sekeres
Journal: Blood Advances
Blood Adv (2022) 6 (17): 5132–5145.
https://doi.org/10.1182/bloodadvances.2022007334
Published: 2022
Includes: Supplemental data